Phathom Pharmaceuticals, Inc. (PHAT) Tops Q2 EPS by 12c

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q2 EPS of ($0.79), $0.12 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $39.5 million versus the consensus estimate of $36.38 million.

For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• HawkEye 360 and Lockheed Martin demonstrate RF tracking at military exercise
• Cloudastructure posts 78% revenue rise in Q1 2026, net loss widens